Exendin-4 reverts behavioural and neurochemical dysfunction in a pre-motor rodent model of Parkinson's disease with noradrenergic deficit.
about
Exendin-4 Treatment Improves LPS-Induced Depressive-Like Behavior Without Affecting Pro-Inflammatory Cytokines.A new approach to disease-modifying drug trials in Parkinson's diseaseActivation of Glucagon-Like Peptide-1 Receptor Promotes Neuroprotection in Experimental Autoimmune Encephalomyelitis by Reducing Neuroinflammatory Responses.Microglial phenotypes in Parkinson's disease and animal models of the disease.GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats.Bacterial melanin improves cognitive impairment induced by cerebral hypoperfusion in rats.
P2860
Exendin-4 reverts behavioural and neurochemical dysfunction in a pre-motor rodent model of Parkinson's disease with noradrenergic deficit.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Exendin-4 reverts behavioural ...... se with noradrenergic deficit.
@en
Exendin-4 reverts behavioural ...... se with noradrenergic deficit.
@nl
type
label
Exendin-4 reverts behavioural ...... se with noradrenergic deficit.
@en
Exendin-4 reverts behavioural ...... se with noradrenergic deficit.
@nl
prefLabel
Exendin-4 reverts behavioural ...... se with noradrenergic deficit.
@en
Exendin-4 reverts behavioural ...... se with noradrenergic deficit.
@nl
P2093
P2860
P1476
Exendin-4 reverts behavioural ...... se with noradrenergic deficit.
@en
P2093
P2860
P304
P356
10.1111/J.1476-5381.2012.02100.X
P407
P577
2012-12-01T00:00:00Z